MiR deregulation in CLL

Advances in Experimental Medicine and Biology

Volumn 792, Issue , 2013, Pages 309-325

  Balatti, Veronica ^a   Pekarky, Yuri ^a   Rizzotto, Lara ^a   Croce, Carlo M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

CLL; MicroRNA; miR 15 16; Tcl1

Indexed keywords

MICRORNA; MICRORNA 15A; MICRORNA 16; MICRORNA 181; MICRORNA 29; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; PROTEIN MDM2; RNA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA 2 GENE; CELL SURVIVAL; CHROMOSOME 13Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DLEU7 GENE; DOWN REGULATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC MARKER; HUMAN; MDM2 GENE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TCL1 GENE; TRAF2 GENE; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84934435028     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-8051-8_14     Document Type: Article

References (96)

1. Adachi M, Tefferi A, Greipp PR, et al. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med. 1990;171(2):559-64.
2. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003;113(6):673-6.
3. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350- 5.
4. Asslaber D, Pinon JD, Seyfried I, et al. MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood. 2010;115(21):4191-7.
5. Auer RL, Riaz S, Cotter FE. The 13q and 11q B-cell chronic lymphocytic leukaemiaassociated regions derive from a common ancestral region in the zebrafish. Br J Haematol. 2007;137(5):443-53.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116 (2):281-97.
7. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996;274(5288):782-4.
8. Berland R, Wortis HH. An NFAT-dependent enhancer is necessary for anti-IgM-mediated induction of murine CD5 expression in primary splenic B cells. J Immunol. 1998;161 (1):277-85.
9. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002;99(10):6955-60.
10. Bommer GT, Gerin I, Feng Y, et al. p53-Mediated activation of miRNA34 candidate tumorsuppressor genes. Curr Biol. 2007;17(15):1298-307.
11. Brockman JA, Scherer DC, McKinsey TA, et al. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol. 1995;15 (5):2809-18.
12. Bullrich F, Croce CM. Molecular biology of chronic lymphocytic leukemia. In: Cheson B, editor. Chronic lymphocytic leukemias, 2nd ed, revised and expanded. New York: Marcel Dekker; 2001. p. 9-32.
13. Bullrich F, Fujii H, Calin G, et al. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res. 2001;61(18):6640-8.
14. Cai X, Hagedorn CH, Cullen BR. Human micrornas are processed from capped, polyadenylated transcripts that can also function as mrnas. RNA. 2004;10:1957-66.
15. Calin GA, Cimmino A, Fabbri M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008;105(13):5166-71.
16. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524-9.
17. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793-801.
18. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004;101(32):11755-60.
19. Calin GA, Pekarsky Y, Croce CM. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007;20(3):425-37.
20. Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26(5):745-52.
21. Chen Z, Hagler J, Palombella VJ, et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev. 1995;9(13):1586-97.
22. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol. 2007;20(3):399-413.
23. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352 (8):804-15.
24. Chung JY, Park YC, Ye H, et al. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci. 2002;115 (Pt 4):679-88.
25. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102(39):13944-9.
26. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647-56.
27. Dighiero G, Binet JL. When and how to treat chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1799-801.
28. Dijkstra MK, van Lom K, Tielemans D, et al. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia. 2009;23(3):625-7.
29. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-6.
30. Efanov A, Zanesi N, Nazaryan N, et al. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. Leukemia. 2010;24(5):970-5.
31. Fabbri M, Bottoni A, Shimizu M, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011;305 (1):59-67.
32. Fabbri M, Ivan M, Cimmino A, et al. Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther. 2007;7(7):1009-19.
33. Ferracin M, Zagatti B, Rizzotto L, et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer. 2010;26(9):123.
34. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-60.
35. Gryshchenko I, Hofbauer S, Stoecher M, et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol. 2008;26(14):2252-7.
36. Haiat S, Billard C, Quiney C, et al. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology. 2006;118(3):281-92.
37. Hammarsund M, Corcoran MM, Wilson W, et al. Characterization of a novel B-CLL candidate gene-DLEU7-located in the 13q14 tumor suppressor locus. FEBS Lett. 2004;556(1-3):75-80.
38. Harfe BD. MicroRNAs in vertebrate development. Curr Opin Genet Dev. 2005;15:410-5.
39. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447(7148):1130-4.
40. Herling M, Patel KA, Khalili J, et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 2006;20(2):280-5.
41. Iorio MV, Croce CM. MicroRNA involvement in human cancer. Carcinogenesis. 2012;33(6):1126-33.
42. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
43. Katsumata M, Siegel RM, Louie DC, et al. Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci U S A. 1992;89(23):11376-80.
44. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91(9):3379-89.
45. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17(1):28-40.
46. Laine J, Kunstle G, Obata T, et al. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000;6(2):395-407.
47. Lee SY, Reichlin A, Santana A, et al. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity. 1997;7(5):703-13.
48. Mackay F, Schneider P, Rennert P, et al. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231-64.
49. Menin C, Scaini MC, De Salvo GL, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst. 2006;98 (4):285-8.
50. Merkel O, Asslaber D, Pinon JD, et al. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle. 2010;9(14):2764-8.
51. Mertens D, Wolf S, Schroeter P, et al. Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood. 2002;99(11):4116-21.
52. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115(3):755-64.
53. Migliazza A, Bosch F, Komatsu H, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood. 2001;97(7):2098-104.
54. Moreno C, Montserrat E. Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use? Haematologica. 2010;95(1):12-5.
55. Mraz M, Malinova K, Kotaskova J, et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 2009;23(6):1159-63.
56. Neilson JR, Auer R, White D, et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia. 1997;11(11):1929-32.
57. Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol. 2006;24(27):4434-40.
58. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363(9403):105-11.
59. Ouillette P, Erba H, Kujawski L, et al. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res. 2008;68(4):1012-21.
60. Palamarchuk A, Efanov A, Nazaryan N, et al. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood. 2010;115(19):3916-22.
61. Palamarchuk A, Yan PS, Zanesi N, et al. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2012;109(7):2555-60.
62. Pekarsky Y, Calin GA, Aqeilan R. Chronic lymphocytic leukemia: molecular genetics and animal models. Curr Top Microbiol Immunol. 2005;294:51-70.
63. Pekarsky Y, Croce CM. Is miR-29 an oncogene or tumor suppressor in CLL? Oncotarget. 2010;1(3):224-7.
64. Pekarsky Y, Koval A, Hallas C, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A. 2000;97(7):3028-33.
65. Pekarsky Y, Palamarchuk A, Maximov V, et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A. 2008;105 (50):19643-8.
66. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006;66(24):11590-3.
67. Pekarsky Y, Zanesi N, Aqeilan RI, et al. Animal models for chronic lymphocytic leukemia. J Cell Biochem. 2007;100(5):1109-18.
68. Planelles L, Carvalho-Pinto CE, Hardenberg G, et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell. 2004;6(4):399-408.
69. Ramkissoon SH, Mainwaring LA, Ogasawara Y, et al. Hematopoietic-specific microRNA expression in human cells. Leuk Res. 2006;30(5):643-7.
70. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893-901.
71. Raveche ES. Possible immunoregulatory role for CD5+ B cells. Clin Immunol Immunopathol. 1990;56(2):135-50.
72. Raveche ES, Salerno E, Scaglione BJ, et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood. 2007;109(12):5079-86.
73. Rondeau G, Moreau I, Bezieau S, et al. Comprehensive analysis of a large genomic sequence at the putative B-cell chronic lymphocytic leukaemia (B-CLL) tumour suppresser gene locus. Mutat Res. 2001;458(3-4):55-70.
74. Rossi S, Shimizu M, Barbarotto E, et al. MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010;116(6):945-52.
75. Sampath D, Liu C, Vasan K, et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood. 2012;119(5):1162-72.
76. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101(4):1220-35.
77. Santanam U, Zanesi N, Efanov A, et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A. 2010;107(27):12210-5.
78. Schuh K, Avots A, Tony HP, et al. Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. Leuk Lymphoma. 1996;23(5-6):583-92.
79. Sieklucka M, Pozarowski P, Bojarska-Junak A, et al. Apoptosis in B-CLL: the relationship between higher ex vivo spontaneous apoptosis before treatment in III-IV Rai stage patients and poor outcome. Oncol Rep. 2008;19(6):1611-20.
80. Smonskey MT, Block AW, Deeb G, et al. Monoallelic and biallelic deletions of 13q14.3 in chronic lymphocytic leukemia: FISH vs miRNA RT-qPCR detection. Am J Clin Pathol. 2012;137:641-6.
81. Stilgenbauer S, Bullinger L, Benner A, et al. Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia. Leukemia. 1999;13(9):1331-4.
82. Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6(13):1586-93.
83. Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228(4706):1440-3.
84. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226(4678):1097-9.
85. Van Antwerp DJ, Martin SJ, Kafri T, et al. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996;274(5288):787-9.
86. van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet. 1999;23(4):474-8.
87. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U S A. 1994;91(26):12530-4.
88. Visone R, Rassenti LZ, Veronese A, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009;114(18):3872-9.
89. Visone R, Veronese A, Rassenti LZ, et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood. 2011;118(11):3072-9.
90. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103(7):2257-61.
91. Wang CY, Mayo MW, Baldwin Jr AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996;274(5288):784-7.
92. Wolf S, Mertens D, Schaffner C, et al. B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions. Hum Mol Genet. 2001;10(12):1275-85.
93. Zanesi N, Pekarsky Y, Trapasso F, et al. MicroRNAs in mouse models of lymphoid malignancies. J Nucleic Acids Investig. 2010;1(1):36-40.
94. Zapata JM, Krajewska M, Morse 3rd HC, et al. TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc Natl Acad Sci U S A. 2004;101(47):16600-5.
95. Zenz T, Mertens D, Dohner H, et al. Molecular diagnostics in chronic lymphocytic leukemia- pathogenetic and clinical implications. Leuk Lymphoma. 2008;49(5):864-73.
96. Zenz T, Mohr J, Eldering E, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2009;113(16):3801-8.